[go: up one dir, main page]

MX2013014708A - Compuestos que inhiben el glioblastoma y su uso. - Google Patents

Compuestos que inhiben el glioblastoma y su uso.

Info

Publication number
MX2013014708A
MX2013014708A MX2013014708A MX2013014708A MX2013014708A MX 2013014708 A MX2013014708 A MX 2013014708A MX 2013014708 A MX2013014708 A MX 2013014708A MX 2013014708 A MX2013014708 A MX 2013014708A MX 2013014708 A MX2013014708 A MX 2013014708A
Authority
MX
Mexico
Prior art keywords
glioblastoma
inhibiting compounds
compounds
treatment
derivatives
Prior art date
Application number
MX2013014708A
Other languages
English (en)
Other versions
MX340816B (es
Inventor
Björn Scheffler
Martin Glas
Matthias Simon
Sabine Gogolok
Daniel Trageser
Roman Reinartz
Anja Wieland
Original Assignee
Univ Bonn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bonn filed Critical Univ Bonn
Publication of MX2013014708A publication Critical patent/MX2013014708A/es
Publication of MX340816B publication Critical patent/MX340816B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • G01N33/5759—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se encuentra relacionada a compuestos que inhiben el glioblastoma, en particular a la amida del ácido gambógico y derivados del mismo para el tratamiento del glioblastoma. Más aún, se revelan métodos para determinar si un tratamiento con los compuestos de la invención es adecuado para un paciente.
MX2013014708A 2011-06-15 2012-06-15 Compuestos que inhiben el glioblastoma y su uso. MX340816B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161497215P 2011-06-15 2011-06-15
PCT/EP2012/061485 WO2012172069A1 (en) 2011-06-15 2012-06-15 Glioblastoma inhibiting compounds and their use

Publications (2)

Publication Number Publication Date
MX2013014708A true MX2013014708A (es) 2014-08-18
MX340816B MX340816B (es) 2016-07-26

Family

ID=46319762

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014708A MX340816B (es) 2011-06-15 2012-06-15 Compuestos que inhiben el glioblastoma y su uso.

Country Status (14)

Country Link
US (1) US9573960B2 (es)
EP (1) EP2721035B1 (es)
JP (1) JP6228113B2 (es)
CN (1) CN103764659A (es)
AU (1) AU2012268984B2 (es)
BR (1) BR112013032360A2 (es)
CA (1) CA2838945A1 (es)
CL (1) CL2013003563A1 (es)
IL (1) IL229767A0 (es)
MX (1) MX340816B (es)
PH (1) PH12013502530A1 (es)
RU (1) RU2014101070A (es)
WO (1) WO2012172069A1 (es)
ZA (1) ZA201309365B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
CA2986930C (en) 2015-06-24 2023-09-26 Duke University Chemical modulators of signaling pathways and therapeutic use
US20180209959A1 (en) * 2015-07-31 2018-07-26 Swedish Health Services Methods and compositions for characterization of glioblastoma multiforme tumors and cancer stem cells
EP3349774A4 (en) * 2015-09-15 2019-03-27 Swedish Health Services METHOD AND COMPOSITE SHEETS FOR CHARACTERIZING GLOBALBLASTOMA MULTIFORM TUMORS AND CANCER STEM CELLS THEREOF
CN105802928A (zh) * 2016-03-30 2016-07-27 苏州偲聚生物材料有限公司 用于检测血清中mgmt抗体的多肽，检测器件和检测试剂盒
CN105796549A (zh) * 2016-04-22 2016-07-27 中国医学科学院基础医学研究所 藤黄酰胺用于制备治疗人神经胶质瘤的药物的用途
CN107475213A (zh) * 2016-06-08 2017-12-15 中国科学院苏州纳米技术与纳米仿生研究所 用于检测血清中mgmt抗体的多肽，检测器件和检测试剂盒
US11311606B2 (en) 2018-03-13 2022-04-26 Georgetown University Enhancing chemotherapy in medulloblastoma and glioblastoma with high basal p53 levels
CN110433154A (zh) * 2019-08-12 2019-11-12 昆明理工大学 藤黄酸的新用途
WO2023183463A1 (en) * 2022-03-23 2023-09-28 University Of Cincinnati Methods of potentiating temozolomide activity against glioblastoma cells
CN117538458B (zh) * 2024-01-09 2024-03-29 中国医学科学院北京协和医院 同时定量分析14种单糖/二糖的液相色谱串联质谱分析方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000045165A1 (en) * 1999-02-01 2000-08-03 Cytovia, Inc. Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products
US6462041B1 (en) * 1999-05-21 2002-10-08 Cytovia, Inc. Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
JP3904364B2 (ja) 2000-03-03 2007-04-11 独立行政法人科学技術振興機構 抗マラリア活性を有する新規化合物
EP1300403A1 (en) * 2001-10-02 2003-04-09 Aventis Pharma S.A. Process for the manufacture of hypoxyxylerone derivatives
WO2008148008A1 (en) * 2007-05-23 2008-12-04 Emory University High throughput bioassay for identifying selective trka receptor agonists, and gambogic amide, a selective trka agonist with neuroprotective activity
CN101289482B (zh) * 2007-09-29 2011-08-31 辽宁利锋科技开发有限公司 藤黄酸苷衍生物和类似物及其制备方法和用途
PA8851101A1 (es) * 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol

Also Published As

Publication number Publication date
BR112013032360A2 (pt) 2017-06-13
PH12013502530A1 (en) 2014-01-27
WO2012172069A1 (en) 2012-12-20
RU2014101070A (ru) 2015-07-20
ZA201309365B (en) 2015-11-25
CA2838945A1 (en) 2012-12-20
JP6228113B2 (ja) 2017-11-08
CL2013003563A1 (es) 2014-06-06
JP2014517025A (ja) 2014-07-17
IL229767A0 (en) 2014-01-30
EP2721035B1 (en) 2018-06-13
US9573960B2 (en) 2017-02-21
AU2012268984B2 (en) 2016-07-14
MX340816B (es) 2016-07-26
US20150148390A1 (en) 2015-05-28
CN103764659A (zh) 2014-04-30
NZ618170A (en) 2015-04-24
EP2721035A1 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
MX2013014708A (es) Compuestos que inhiben el glioblastoma y su uso.
GT201400196A (es) Compuestos de heterociclilo
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CR20140519A (es) Derivados de benzamida para la inhibición de la actividad de abl 1, abl 2 y bcr-abl 1
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
ECSP13013074A (es) Nuevos derivados de piridina
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
MX2015011273A (es) Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacio nados con la fosfoinositida 3-cinasa delta.
NI201400078A (es) Derivados de lactamas útiles como inhibidores mutantes de idh1
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CR20150250A (es) Nuevos derivados de piridina
UY34472A (es) Derivados modificados de 4-fenil-piridina
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CR20150447A (es) Nuevos derivados de pirazol
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
CR20150204A (es) Nuevos derivados de piridina
CR20140554A (es) Compuestos de acido dimetil-benzoico
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
MX371356B (es) Profarmacos de aminoquinazolina inhibidora de cinasa.
CR20140435A (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
DOP2016000120A (es) Nuevos inhibidores de dgat2
CL2014001704A1 (es) Derivados de amida ciclica como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa; composicion farmaceutica que los comprende y el uso de los mismos en la prevencion o tratamiento de enfermedades tales como la diabetes.

Legal Events

Date Code Title Description
FG Grant or registration